Liver cancer is one of the most deadly types of cancer worldwide. Most patients are diagnosed at an advanced stage, which leaves them with few treatment options. Unfortunately, the first-line drugs are not very effective and offer only modest clinical benefits. Over the past few years, scientists have been trying to develop new therapies for HCC by analyzing specific genetic abnormalities. One of the most common mutations in HCC occurs in CTNNB1 gene, which encodes a protein called β-catenin. However, no therapies targeting β-catenin-related pathways have been approved yet. With this goal, the researchers first conducted a screening experiment using...